JP2022545158A5 - - Google Patents

Info

Publication number
JP2022545158A5
JP2022545158A5 JP2022503825A JP2022503825A JP2022545158A5 JP 2022545158 A5 JP2022545158 A5 JP 2022545158A5 JP 2022503825 A JP2022503825 A JP 2022503825A JP 2022503825 A JP2022503825 A JP 2022503825A JP 2022545158 A5 JP2022545158 A5 JP 2022545158A5
Authority
JP
Japan
Application number
JP2022503825A
Other languages
Japanese (ja)
Other versions
JP2022545158A (ja
JPWO2021032937A5 (https=
JP7566870B2 (ja
Filing date
Publication date
Priority claimed from PCT/GB2019/052359 external-priority patent/WO2021032936A1/en
Application filed filed Critical
Publication of JP2022545158A publication Critical patent/JP2022545158A/ja
Publication of JP2022545158A5 publication Critical patent/JP2022545158A5/ja
Publication of JPWO2021032937A5 publication Critical patent/JPWO2021032937A5/ja
Application granted granted Critical
Publication of JP7566870B2 publication Critical patent/JP7566870B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022503825A 2019-08-21 2020-02-13 酵素阻害剤 Active JP7566870B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2019/052359 WO2021032936A1 (en) 2019-08-21 2019-08-21 Enzyme inhibitors
GBPCT/GB2019/052359 2019-08-21
PCT/GB2020/050332 WO2021032937A1 (en) 2019-08-21 2020-02-13 Enzyme inhibitors

Publications (4)

Publication Number Publication Date
JP2022545158A JP2022545158A (ja) 2022-10-26
JP2022545158A5 true JP2022545158A5 (https=) 2023-02-20
JPWO2021032937A5 JPWO2021032937A5 (https=) 2023-02-20
JP7566870B2 JP7566870B2 (ja) 2024-10-15

Family

ID=67777359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503825A Active JP7566870B2 (ja) 2019-08-21 2020-02-13 酵素阻害剤

Country Status (15)

Country Link
US (1) US20220363668A1 (https=)
EP (1) EP4017587A1 (https=)
JP (1) JP7566870B2 (https=)
KR (1) KR20220051207A (https=)
CN (1) CN114269430A (https=)
AR (1) AR118085A1 (https=)
AU (1) AU2020333222A1 (https=)
BR (1) BR112022000936A2 (https=)
CA (1) CA3147228A1 (https=)
CO (1) CO2022000266A2 (https=)
IL (1) IL289783A (https=)
MX (1) MX2022002069A (https=)
PH (1) PH12022550078A1 (https=)
TW (1) TW202115033A (https=)
WO (2) WO2021032936A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021032935A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
WO2025153806A1 (en) * 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
CN103415301A (zh) * 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
GB2517908A (en) * 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
WO2015171527A1 (en) * 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
WO2017123518A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
AU2017269256B2 (en) 2016-05-23 2021-02-25 The Rockefeller University Aminoacylindazole immunomodulators for treatment of autoimmune diseases
WO2018093695A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
EP3541381B1 (en) 2016-11-18 2022-12-28 Merck Sharp & Dohme LLC Inhibitors of factor xiia
JP2021504490A (ja) 2017-11-29 2021-02-15 ザ ロックフェラー ユニバーシティーThe Rockefeller University 自己免疫疾患治療用ピラノピラゾールおよびピラゾロピリジン免疫調節薬
WO2021032935A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)